Biotech Boulevard
Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
GEN's Biotech Boulevard
All  All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   0  1  2  3  4  5  6  7  8  9   
  • Genea Stem Cells

    Genea Stem Cells (GSC) develops disease-specific pluripotent and differentiated human cells for use in drug discovery and research. Based on the world’s largest private bank of human embryonic stem cells (about 100 lines/30 diseases), GSC supplies application-ready, disease-affected and control differentiated cell types and works collaboratively with industry for custom-developed cell-based assay solutions in drug development. All of GSC’s cell products are genetically unmodified human cells - the most accurate in vitro reflection of clinical conditions.

  • GigaGen

    GigaGen envisions a future where doctors routinely use an immune "fingerprint" to help manage complex medical problems such as transplantation, autoimmune disease, and cancer. The GigaMune™ technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize your immune system into an immune "fingerprint".

  • Global Blood Therapeutics

    Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to improve the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options. The company's unique SHAPE Platform is enabling the discovery and development of small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits.

  • Gradalis

    Gradalis is a privately-held, fully-integrated biotechnology company based in Dallas, Texas that is developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in the area of cancer. The company has two platforms:  one focused on personalized autologous vaccines and the other  on bifunctional short hairpin RNA delivered via a proprietary lipoplex system. Recently-published data showed that FANG, the company’s autologous tumor vaccine, showed significant survival benefit in patients with advanced disease for multiple types of cancer. Gradalis has its own state of the art GMP manufacturing facility, as well as a strategic partnership with Mary Crowley Cancer Research Centers for early stage clinical development of Gradalis products.  

  • Helmedix

    Helmedix, a start-up company from the ithree institute at the University of Technology Sydney, is a biopharmaceutical company developing therapies for autoimmune diseases based on peptides derived from a helminth parasite. Helmedix will be managed as a virtual company, based in Sydney, with research contracted to Dr Donnelly’s team at the ithree institute.

  • Hepregen

    Hepregen's mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients' lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen's platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery.


  • HiberGene

    HiberGene is developing a molecular diagnostic test for meningitis which can be used to test for the presence of the two most common forms of the disease, Meningococcus and Pneumococca. The test uses a rapid isothermal amplification platform allowing accurate results to be delivered in less than forty minutes. The company intends to develop a range of tests for a number of infectious human diseases including healthcare associated infections and sexually transmitted Infections.

  • Hookipa Biotech

    Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative prophylactic and therapeutic vaccines. The Vaxwave® technology is a vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and build a robust product pipeline. Hookipa has recently moved into its BSL2 facility at the Campus Vienna Biocenter.

  • ImmusanT

    ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management.

  • JB Therapeutics

    JB Therapeutics, a clinical stage biopharmaceutical company, is developing JBT-101 a nanomolar cannabinoid agonist which activates the CB2 receptor present on immune cells and fibroblasts. Upon binding CB2, JBT-101 stimulates the production of specific lipid mediators (PGJ2, LXA4) which act to turn off inflammation and fibrosis. The product is a pharmaceutical capsule containing a pure synthetic derivative of THC with minimal blood brain barrier penetration. It is currently being developed as a potential disease modifying treatment for the orphan disease scleroderma.

© 2012 Genetic Engineering & Biotechnology News. All Rights Reserved.
Back to